New Analysis of Rosiglitazone (Avandia) Data on Heart Risk “Uncertain”
A new analysis of data on the effects of the diabetes drug rosiglitazone (Avandia) found that the risk for heart attack and death from cardiovascular disease is “uncertain”. The analysis states that it neither increases nor decreases risk. Authors say an earlier study, which found the drug associated with increased risk for myocardial infarction and cardiovascular death, had several flaws. The authors re-analyzed the data from the earlier trial. Authors say that the risk controversy will only be solved with “prospective clinical trials designed for the specific purpose of establishing the cardiovascular benefit or risk of rosiglitazone.”
